Collegium Pharmaceutical (COLL) Q4 FY2023 earnings: revenue $150 million, up 15.5% on the year

Collegium Pharmaceutical, Inc. (COLL) reported revenue of $150 million for Q4 FY2023, the quarter ended 31 December 2023, up 15.5% on the same quarter a year earlier. Net income was $32 million, and diluted earnings per share $0.82. The figures are the company's own, from the 10-K it filed with the SEC on 22 February 2024.

Revenue$150 millionup 15.5%

Net income$32 million

Diluted EPS$0.82

QuarterQ4 FY2023ended 31 December 2023

The quarter, against the one before and a year earlier

Line	Q4 FY2023	Q3 FY2023	A year earlier	Change on the year
Revenue	150	137	n/a	n/a
Cost of revenue	55.1	56.4	n/a	n/a
Gross profit	94.6	80.3	n/a	n/a
Gross margin	63.2%	58.7%	n/a
Selling, general and administrative	32.9	35.3	n/a	n/a
Operating income	61.7	45.0	n/a	n/a
Operating margin	41.2%	32.9%	n/a
Interest expense	19.3	20.8	n/a	n/a
Pre-tax income	46.7	28.8	n/a	n/a
Income tax	14.8	8.1	n/a	n/a
Effective tax rate	31.6%	28.3%	n/a
Net income	31.9	20.6	n/a	n/a
Net margin	21.3%	15.1%	n/a
Diluted EPS	$0.82	$0.53	n/a	n/a

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

Line	Q4 FY2023	Q3 FY2023	A year earlier	Change on the year
Operating cash flow	73.3	74.0	n/a	n/a
Capital expenditure	0.2	0.1	n/a	n/a
Free cash flow	73.2	74.0	n/a	n/a
Free cash flow margin	48.9%	54.1%	n/a
Cash from investing	-25.1	-3.8	n/a	n/a
Cash from financing	-67.8	-95.4	n/a	n/a
Depreciation and amortisation	35.5	37.2	n/a	n/a
Share-based compensation	7.0	7.0	n/a	n/a
Diluted shares, weighted	41m	42m	n/a	n/a
Shares outstanding at period end	32m	33m	n/a	n/a

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

Line	Q4 FY2023	Q3 FY2023	A year earlier	Change on the year
Shareholders' equity	195	179	n/a	n/a
Debt	667	711	n/a	n/a
Operating lease liabilities	6.1	6.4	n/a	n/a
Other liabilities	275	281	n/a	n/a
Total liabilities and equity	1,143	1,178	n/a	n/a
Fixed assets	16.0	16.6	n/a	n/a
Goodwill	134	134	n/a	n/a
Intangible assets	422	456	n/a	n/a
Investments	71.6	46.0	n/a	n/a
Cash and equivalents	239	259	n/a	n/a
Receivables	180	182	n/a	n/a
Inventory	32.3	34.1	n/a	n/a
Other assets	49.4	50.3	n/a	n/a
Total assets	1,143	1,178	n/a	n/a

Questions

What was Collegium Pharmaceutical's revenue in Q4 FY2023?

Collegium Pharmaceutical (COLL) reported revenue of $150 million for Q4 FY2023, the quarter ended 31 December 2023, up 15.5% on the same quarter a year earlier.

How much did Collegium Pharmaceutical earn in Q4 FY2023?

Net income for Q4 FY2023 was $32 million, and diluted earnings per share $0.82.

When did Collegium Pharmaceutical report Q4 FY2023 results?

Collegium Pharmaceutical filed its 10-K for the quarter ended 31 December 2023 with the SEC on 22 February 2024.

Quarterly results, the last 12 quarters

	Q3 FY2023	Q4 FY2023	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025	Q1 FY2026	Q2 FY2026
Revenue	137	150	145	145	159	182	178	188	209	205	194	200
Cost of revenue	56.4	55.1	53.5	54.5	62.5	83.7	80.4	79.6	80.2	77.1	76.3	89.6
Gross profit	80.3	94.6	91.5	90.8	96.8	98.3	97.3	108	129	128	117	110
Gross margin	59%	63%	63%	63%	61%	54%	55%	58%	62%	62%	61%	55%
SG&A	35.3	32.9	42.0	43.3	62.0	63.1	76.4	73.6	67.1	67.6	86.3	107
Operating income	45.0	61.7	49.5	47.5	34.8	38.1	21.7	35.1	62.1	60.8	30.9	3.7
Operating margin	33%	41%	34%	33%	22%	21%	12%	19%	30%	30%	16%	2%
Interest expense	20.8	19.3	17.3	15.6	18.4	22.7	20.8	20.5	21.8	19.3	15.9	19.5
Pre-tax income	28.8	46.7	36.6	29.1	15.6	17.3	3.1	17.0	43.4	29.0	18.7	-13.5
Tax rate	28%	32%	24%	33%	40%	27%	23%	30%	27%	42%	23%	n/a
Net income	20.6	31.9	27.7	19.6	9.3	12.5	2.4	12.0	31.5	17.0	14.5	-15.1
Net margin	15%	21%	19%	13%	6%	7%	1%	6%	15%	8%	7%	-8%
Diluted EPS	$0.53	$0.82	$0.71	$0.52	$0.27	$0.36	$0.07	$0.34	$0.84	$0.46	$0.40	-$0.46
Operating cash flow	74.0	73.3	61.9	67.4	-9.0	84.6	55.4	72.4	78.4	123	57.1	71.3
Capital expenditure	0.1	0.2	0.6	0.3	0.2	0.6	0.8	0.1	0.2	0.7	0.3	0.5
Free cash flow	74.0	73.2	61.4	67.1	-9.2	84.1	54.6	72.4	78.2	122	56.8	70.8
Buybacks	n/a	n/a	n/a	n/a	0.0	n/a	n/a	25.1	0.0	n/a	n/a	0.0
Shares outstanding	33m	32m	33m	32m	32m	31m	32m	32m	32m	32m	32m	32m
Filing	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q

Each quarter as filed, linked to its filing.

Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-K for the period ended 31 December 2023, filed 22 February 2024, accession 0001558370-24-001526: the filing on EDGAR. All of Collegium Pharmaceutical, Inc.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install